Screener
AOCI at other companies
Other financials
Where this comes from
Reported directly by Integra LifeSciences in its filing.
Tagged under the XBRL concept us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax.
The source filing: Integra LifeSciences’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:03 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000917520-26-000058
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Preferred stock; no par value; 15,000 authorized shares; none outstanding | — | — |
| Common stock; $0.01 par value; 240,000 authorized shares; 92,130 and 92,286 issued at June 30, 2026 and December 31, 2025, respectively | 921 | 923 |
| Additional paid-in capital | 1,346,265 | 1,338,386 |
| Treasury stock, at cost; 14,351 shares and 14,399 shares at June 30, 2026 and December 31, 2025, respectively | (686,918) | (689,210) |
| Accumulated other comprehensive loss | (40,197) | (30,077) |
| Retained earnings | 423,306 | 423,441 |
| Total stockholders’ equity | 1,043,377 | 1,043,463 |
| Total liabilities and stockholders’ equity | $3,563,490 | $3,602,001 |
Item 1. Financial Statements
FAQ
- What is Integra LifeSciences's AOCI?
- Integra LifeSciences (IART) reported AOCI of -$40.2M in Q2 2026.
- How has Integra LifeSciences's AOCI changed year-over-year?
- Integra LifeSciences's AOCI decreased by 30.1% year-over-year, from -$30.91M to -$40.2M.
- What is the long-term trend for Integra LifeSciences's AOCI?
- Over 5 years (2020 to 2025), Integra LifeSciences's AOCI has grown at a -16.5% compound annual growth rate (CAGR), from -$74.06M to -$30.08M.
- What does AOCI mean?
- Accumulated gains and losses bypassing the income statement — unrealized investment gains/losses, currency translation, pension adjustments, and hedge results.
Ask your AI about Integra LifeSciences's aoci.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude